Tylenol Arthritis Pain Caplets on recall
This article was originally published in The Tan Sheet
McNeil Consumer Healthcare expands a voluntary recall of its arthritis analgesic from five lots to all available lots following consumer reports of a moldy odor associated with the product. The Johnson & Johnson unit and FDA said Dec. 18 certain lots of the Tylenol Arthritis Pain product in 100-count bottles had traces of a chemical from treated wooden pallets, though all adverse events associated with the resulting odor have been temporary and non-serious. McNeil said it plans to move production to a new facility and reintroduce the product
You may also be interested in...
McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall
Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.
Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.